5187 CREATE MEDIC CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

5187

TSE Standard

CREATE MEDIC CO.,LTD.

918

JPY

(+0.33%)

Jan 10, 3:30 pm JST

5.79

USD

Jan 10, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	10,830	984	952	659	71.2	37	Feb 10, 2021	J-GAAP
Dec, 2021	11,698	866	1,009	660	72.6	37	Feb 10, 2022	J-GAAP
Dec, 2022	12,326	741	834	482	53.0	37	Feb 13, 2023	J-GAAP
Dec, 2023	12,585	803	872	154	16.9	37	Feb 14, 2024	J-GAAP
Dec, 2024 Guidance	13,032	868	900	967	112.6	39	Feb 14, 2024	J-GAAP
YoY	+3.6%	+8.1%	+3.2%	+527.9%	+565.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 13, 2019	10,930	1,000	1,010	700	37	J-GAAP
Results	Feb 12, 2020	10,843	1,083	1,065	725	37	J-GAAP
Dec, 2020	Feb 12, 2020	Available in future release
	May 1, 2020
Results	Feb 10, 2021
Dec, 2021	Feb 10, 2021
	Oct 28, 2021
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
Results	Feb 13, 2023
Dec, 2023	Feb 13, 2023
	Oct 31, 2023
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024	13,032	868	900	967	39	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 1999	7,076	+6.0	Available in future release
Dec, 2000	7,266	+2.7
Dec, 2001	7,700	+6.0
Dec, 2002	7,861	+2.1
Dec, 2003	8,072	+2.7
Dec, 2004	8,219	+1.8
Dec, 2005	8,488	+3.3
Dec, 2006	8,439	-0.6
Dec, 2007	8,878	+5.2
Dec, 2008	9,058	+2.0
Dec, 2009	9,017	-0.5
Dec, 2010	9,097	+0.9
Dec, 2011	9,325	+2.5
Dec, 2012	9,331	+0.1
Dec, 2013	9,880	+5.9
Dec, 2014	9,939	+0.6
Dec, 2015	9,650	-2.9
Dec, 2016	10,003	+3.7
Dec, 2017	10,393	+3.9
Dec, 2018	10,796	+3.9
Dec, 2019	10,843	+0.4
Dec, 2020	10,830	-0.1
Dec, 2021	11,698	+8.0
Dec, 2022	12,326	+5.4
Dec, 2023	12,585	+2.1
Dec, 2024 Guidance	13,032	+3.6	868	+8.1	900	+3.2	112.6	+566.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	12,326	741	6.01	3.33	2.61	0.67	53.0
Dec, 2023	12,585	803	6.38	1.04	0.81	0.66	16.9
Dec, 2024 Guidance	13,032	868	6.66	6.44	5.14	0.69	112.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	12,585	1,562	1,575	957	98.2
Fiscal Year	Dec, 2023	Dec, 2005	Dec, 2005	Dec, 2005	Dec, 2005

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	6,219	379	469	252	27.7	20	Feb 10, 2022	J-GAAP
Jul - Dec, 2022	6,405	370	364	216	23.8	20	Feb 13, 2023	J-GAAP
Jul - Dec, 2023	6,560	468	501	-162	-17.8	20	Feb 14, 2024	J-GAAP
Jul - Dec, 2024 Guidance	6,732	577	555	417	48.6	20	Aug 5, 2024	J-GAAP
YoY	+2.6%	+23.3%	+10.8%	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	866	663	1,248	-585	-442	3,413	18.88	J-GAAP
Dec, 2022	741	521	478	43	-356	3,702	19.62	J-GAAP
Dec, 2023	803	335	698	-363	-362	3,770	19.58	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	9,047	621	755	483	53.2	90.5	Oct 31, 2022	J-GAAP
Jan - Sep, 2023	9,168	612	651	9	1.1	74.7	Oct 31, 2023	J-GAAP
Jan - Sep, 2024	9,512	521	545	744	83.9	60.6	Oct 31, 2024	J-GAAP
YoY	+3.8%	-14.9%	-16.3%	+8,166.7%	+7,810.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	3,279	120	79	-1	-0.1	3.7	Feb 13, 2023	J-GAAP
Jan - Mar, 2023	2,870	125	119	129	14.3	4.4	May 8, 2023	J-GAAP
Apr - Jun, 2023	3,155	210	252	187	20.6	6.7	Aug 4, 2023	J-GAAP
Jul - Sep, 2023	3,143	277	280	-307	-36.2	8.8	Oct 31, 2023	J-GAAP
Oct - Dec, 2023	3,417	191	221	145	15.9	5.6	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	2,976	98	106	59	6.5	3.3	May 7, 2024	J-GAAP
Apr - Jun, 2024	3,324	193	239	491	54.8	5.8	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	3,212	230	200	194	21.9	7.2	Oct 31, 2024	J-GAAP
YoY	+2.2%	-17.0%	-28.6%	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	3,110	+5.2	Available in future release
Jan - Mar, 2020	2,322	-0.2
Apr - Jun, 2020	2,760	-2.5
Jul - Sep, 2020	2,645	+2.7
Oct - Dec, 2020	3,103	-0.2
Jan - Mar, 2021	2,581	+11.2
Apr - Jun, 2021	2,898	+5.0
Jul - Sep, 2021	2,852	+7.8
Oct - Dec, 2021	3,367	+8.5
Jan - Mar, 2022	2,892	+12.0
Apr - Jun, 2022	3,029	+4.5
Jul - Sep, 2022	3,126	+9.6
Oct - Dec, 2022	3,279	-2.6
Jan - Mar, 2023	2,870	-0.8
Apr - Jun, 2023	3,155	+4.2
Jul - Sep, 2023	3,143	+0.5
Oct - Dec, 2023	3,417	+4.2
Jan - Mar, 2024	2,976	+3.7
Apr - Jun, 2024	3,324	+5.4
Jul - Sep, 2024	3,212	+2.2	230	-17.0	200	-28.6	21.9	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,417	800	797	491	54.8
Fiscal Year	Dec, 2023	Dec, 2005	Dec, 2005	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	1,563.55	78.7	18,075	14,220	10,931	0.06	Feb 10, 2022	J-GAAP
Dec, 2022	1,618.10	78.0	18,865	14,723	10,769	0.05	Feb 13, 2023	J-GAAP
Dec, 2023	1,641.59	77.6	19,258	14,944	10,586	0.05	Feb 14, 2024	J-GAAP
Jan - Sep, 2024	1,742.18	79.8	18,825	15,019	10,981	0.05	Oct 31, 2024	J-GAAP

CREATE MEDIC CO.,LTD.(5187) Financial Results